<DOC>
	<DOCNO>NCT00195299</DOCNO>
	<brief_summary>This open-label , exploratory , biomarker study intravenous temsirolimus give weekly 3 week newly diagnose , advanced stage head neck cancer subject prior begin standard therapy specific disease . The primary objective study identify biomarkers temsirolimus activity .</brief_summary>
	<brief_title>Study Evaluating Temsirolimus Advanced Stage Squamous Cell Carcinoma Head &amp; Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Subjects newly diagnose , advanced stage , head neck squamous cell carcinoma oral cavity , oral pharynx , hypopharynx larynx . Subjects willing undergo tumor biopsy . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 . Age &gt; /= 18 year . Subjects receive anticoagulation therapy . Presence unstable angina , recent myocardial infarction ( within previous 6 month ) , use ongoing maintenance therapy lifethreatening ventricular arrhythmia . Prior cancer therapy ( chemotherapy , hormonal therapy , radiotherapy , immunotherapy ) investigational agent head neck cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Head</keyword>
	<keyword>Neck</keyword>
</DOC>